n,CAPONE ET AL. therapeutic monitoring of these drugs is deemed appropriate (7) (8) . A recent promising alternative to standardized and fully validated LCIUV and LC/MS methods is represented by immunoassays, which offer the opportunity to minimize sample pre-treatment (no need of drug purification), thus reducing the time between drawing the blood sample and measuring the drug concentration, an important aspect in high-throughput analyses.
To optimize the immunosuppressive regimen, frequent measurements of trough blood levels of both drugs are necessary because of the narrow therapeutic range. This eventuality needs major expertise and availability of specific analytical techniques, not always present in the same livingplace of transplanted patients. All these conditions could improve the cost-benefit ratio of therapeutic drug monitoring and help physicians to take appropriate and fast decisions about the correct management of immunosuppressive dosages. In this setting, the correct storage of blood samples has an important role. In fact, drug degradation in the haematic matrix and a correct handling of blood samples still represent a key factor for effective therapeutic drug monitoring.
Regarding Siro, Salm and colI. reported a stability at 4°C or 30°C in light and dark up to 8 days, with a percentage decrease less than 10% for control at 15.0 ug/l; moreover, samples stored at -80°C for 6 weeks were stable after one, two or three freeze-thaw cycles (9) . Besides, Siro was found to be stable in blood for 30 days ifstored at 4°C or 30°C (10) , and a significant reduction in Siro blood concentrations was reported for samples stored at -40°C for 6 months which had undergone two freeze-thawing cycles (11) .
With regard to Rad, Salm and colI. reported a stability of 8 months when blood samples were stored at -80°C; samples were stable at room temperature and exposed to light for 6 hours (12) . Baldelli and colI. reported no significant loss in Rad blood concentrations after three freeze-thaw cycles, with storage at room temperature for 15 h or after 31 days below -20°C (13) .
The present study is aimed at investigating Siro and Rad short and long term stability in whole blood samples from kidney transplant patients. Short term stability studies were aimed at investigating the possibility of transporting samples from hospitals to laboratory at room temperature even in hot months without refrigerating them. In particular, samples were stored at 30°C in light for three or seven days. Long term stability studies were aimed at verifying the possibilityof storing samples in basic freezers, without resorting to more expansive equipment; for this purpose, samples were stored at -20°C for 30,60 or 90 days and analysed after a single freeze-thaw cycle.
MATERIALS AND METHODS
Siro blood concentrations were measured by Microparticle Enzyme ImmunoAssay (MEIA) on an IMx analyzer (Abbott Diagnostics Division). MEIA reagents and consumables were from Abbott Diagnostics Division (Abbott Park, IL, USA).
Rad blood concentrations were measured by Fluorescence Polarization ImmunoAssay (FPIA) (Innofluor" Certican assay Seradyn Inc.) on TDx® analyzer (Abbott Diagnostics Division). FPIA reagents and consumables were from Seradyn Inc. (Indianapolis, IN, USA).
In addition, both Siro and Rad blood concentrations were measured by liquid chromatography mass spectrometric method (LC/ESI-MSMS). Siro and 32desmethoxyrapamycin (DMR, used as internal standard) were from Wyeth-Ayerst (Princeton, NY, USA); Rad was from Novartis Pharma (AG, Basel, Switzerland). HPLC grade solvents were from Carlo Erba (Milan, Italy). A Luna®Cl8 (150 x 2.0 mm, 5 urn, 100 A) column (Phenomenex, Torrance, USA) was used for the HPLC elution of Siro, Rad and DMR. A column oven with a temperature control module (Lab Service Analytica, Italy) was used to keep the column temperature at 50°C during chromatographic elutions. LC/ESI-MSMS analyses were carried out by using a SpectraSystem P2000 HPLC modular system equipped with an AS3000 autosampler (ThermoElectron Corporation, San Jose, CA, USA) and a LCQ™DECA ion trap mass spectrometer, equipped with an electrospray ion source (Thermo).
Siro Microparticle Enzyme Immunoassay (MEIA) method
Whole blood samples were purified according to the Abbott IMx instructions. Briefly, analyte was extracted using a mixture of 150 III whole blood EDTA sample (or controls) and 300 III of the precipitation reagent. Samples were centrifuged and the supernatant was decanted into the sample well of the IMx reaction cell for the subsequent analysis. Calibration curves were constructed using rapamycin concentrations of 0.0, 3.0, 6.0, 12.0,20.0 and 30.0 ng/ml; quality control samples at three levels of concentration (5.0, 11.0 and 22.0 ng/ml) were used for daily quality control and to verify MEIA accuracy and precision.
Abbott Diagnostic Division reported an analytical sensitivity (defined as the lowest measurable concentration of rapamycin that can be distinguished from zero) ::;; 1.5 ng/mL, calculated as the concentration at two standard deviations from the mean rate count signal of the IMx rapamycin calibrator at 0 ng/mL. Accuracy, intra-and inter-day precision (expressed as CV%) ranged between -0.9% and -4.5%, 2.7% and 6.3%, 1.3% and 1.8%, respectively (14) . Data were within FDA requirements (15) .
Rad Fluorescence Polarization Immunoassay (FPIA) method
Whole blood samples treated with EDTA were purified and analyzed according to manufacturer's specifications. Briefly, 600 III samples aliquot were added with 700 III of methanol and 100 IIIof Innofluor" Certican" precipitation reagent in a centrifuge tube. Samples were capped and vigorously mixed/vortexed for at least 10 seconds. The samples were then centrifuged for 8 minutes at 13400 x g, and 300 III aliquots of the supernatant were pipetted into the sample cartridges loaded into the TDx® carousel for subsequent analysis. Calibration curves were constructed using Rad concentrations of 0.0,2.59,4.73,9.06, 18.11 and 39.78 ng/ml; quality control samples at three levels of concentration (3.95, 11.12 and 22.05 ng/ml) were used for daily quality control and to verify FPIA accuracy and precision.
Seradyn Innofluor reported an analytical sensitivity (defined as the lowest measurable concentration of everolimus that can be distinguished from zero) of 0.80 ng/mL, calculated as the concentration at two standard deviations from the mean rate count signal of the TDx everolimus calibrator at 0 ng/mL. Accuracy, intra-and inter-day precision (expressed as CV%) ranged between -5.8% and -11.4%, 6.9% and 10.5%, 7.7% and 10.4%, respectively. Data were within FDA requirements (15) .
LCIESI-MSMS method
Stock and working solutions of Siro, Rad and DMR used for the preparation of blood samples employed in the construction of calibration curves and quality control samples were prepared in methanol. Stock solutions were stored at -80°C; working solutions were kept at -20°e.
The quantification of Siro blood concentrations by liquid chromatography mass spectrometric method (LC/ESI-MSMS) was performed as previously reported (16) , and was based on the isolation and subsequent fragmentation of the [MtNa]" pseudo-molecular ion at ml z 936. 5 (15) . The LC/ESI-MSMS method was characterised by a LOD of 0.7 ng/mL and a LLOQ of 2.4 ng/mL for sirolimus (16) and by a LOD of 0.6 ng/mL and a LLOQ of2.9 ng/mL for everolimus.
The data of the inaccuracy, intra-and inter-day precision for both analytes were within FDA requirements (15) .
Stability studies: sample collection and storage
Stability studies were carried out on residual blood samples from kidney transplant patients. For both Siro and Rad, short term and long term stability were tested. All samples were analysed in triplicate and the mean values were considered.
Short term stability was tested by analysing samples immediately after collection (ST o ) and after storage at 30°C in light for three (ST) and seven (ST 7 ) days. In the case of Siro, a total of 35 samples were collected from 30 patients, while a total of23 samples from 15 patients were collected for Rad.
Long term stability was tested by analysing samples immediately after collection (LT o ) and after storage at -20°C for 30 days (LT 30 ) , 60 days (LT 60 ) or 90 days (LT go ) ' In order to exclude possible variations in drug concentrations due to freeze-thaw cycles, samples were divided into three aliquots, each one analysed immediately after collection and after storage for one of the three periods and after a single freeze-thaw cycle. In the case ofSiro a total of 138 samples were analysed from 46 residual blood samples collected from 35 patients (46 stored for 30 days, 46 stored for 60 days and 46 stored for 90 days); for Rad a total of90 samples were analysed from 30 residual blood samples collected from 18 patients (30 stored for 30 days, 30 stored for 60 days and 30 stored for 90 days).
In order to exclude a potential cross-reactivity of both immunoassays towards molecules having slight structural variations and biological activities, a limited number of samples were analysed by LC/ESI-MSMS as confirmatory method. In particular, 15samples for Siro and 10 samples for Rad were used for short term stability study and 36 samples for Siro (12 stored for LT 30 , 12 for LT 60 and 12 for LT go ) and 24 samples for Rad (8 stored for LT 30 , 8 for LT 60 and 8 for LT go ) were used for long term stability study.
Statistical analysis
All data were expressed as mean ± standard deviation 
RESULTS

Short term stability
In Table I panels A and B, the mean concentrations obtained at baseline (ST o ) and after storage at 30°C in light for three (ST3) or seven days (ST7) were reported for both Siro and Rad. Accuracy of quantifications of ST 3 and ST 7 versus the corresponding ST o value was also evaluated.
Regarding the immunoassay methods, blood samples containing Siro showed concentrations in the range 6.9 -18.9 ng/rnl, Samples analysed immediately after collection had a mean concentration of 9.6 ± 3.7 ng/ml; after three days of storage at 30°C in light a mean concentration of 9.4 ± 3.0 ng/ml was found, corresponding to a decrement of -2.0%. After seven days of storage at 30°C in light a mean concentration of9.1 ±2.9 ng/ml was found, corresponding to a decrement of -5.2% with respect to the ST o value. If a certain grade of drug degradation is present, it remains uniform within the whole range of analysed concentrations, as shown by the substantial constancy in standard deviations associated to the mean concentrations. No statistically significant differences were found between ST 3 or ST 7 values and ST o values. Blood samples containing Rad had concentrations in the range 1.7 -17.6 ng/ml; the mean concentration measured immediately after collection (ST o ) was 8.2 ± 4.0 ng/ml, After three days of storage at 30°C in light a mean concentration of 7.7 ± 3.7 ng/ml was obtained, corresponding to a variation of -6.1%; such values remained unchanged after seven days of storage (7.7 ± 3.7 ng/ml with a variation of -6.1%). analysis highlighted a good agreement between sirolimus concentrations measured immediately after collection (ST0) and after the storage period (ST3and ST7)' confirmed by the slight number of values (l and 2 specimens, respectively) exceeding the fixed range ofmean±2SD (Fig. 2, panels a and b ).
In the case ofRad, the correlation equations were:
ST 3 = 0.620 + 0.864 LT o ' r = 0.948; ST 7 = 0.733 + 0.843 ST o ' r = 0.908. Rad samples analysed after three and seven days showed a higher closeness to the reference values with respect to Siro, as shown by the proximity of the correlation curves (straight and dash lines, panel b) to the y = x curve (dotted line). The Bland-Altman analysis showed a good agreement between everolimus concentrations measured immediately after collection (ST o ) and after storage period (ST 3 and ST 7 ) , confirmed by the slight number of values (2 specimens in both cases) exceeding the fixed range of mean±2SD (Fig. 2 , panels c and d).
Long term stability
In Table I -.. LT o ' r = 0.786. Indeed, the Bland-Altman analysis highlighted similar good agreements between sirolimus concentrations measured immediately after collection (LT0) and after storage periods (LT30' LT 60 and LT 90 ) , confirmed by the nearly equal low number of values (3, 3 and 4 samples, respectively) exceeding the fixed range of mean±2SD ( Fig. 4 , panels a-c).
. Long term stability study ofsirolimus (Siro) and everolimus (Rad): correlation between concentrations ofsamples stored at -20 DCfor 30 (LT 3 0' panels a and d), 60 (LT 6 / f panels b and e) and 90 (LT 9 / f panels c andf) days and the reference values, LT n (panels a, band c for Siro and panels d, e andffor Rad). Straight curve represents regression line for LT 3 0' LT
In Fig. 3 concentrations of Rad stored samples (LT 30 , LT 60 and LT 90 , panels d, e and f, respectively) were correlated with the reference value (LT0)' Despite the almost constant average concentration values obtained for samples stored for 60 and 90 days (see Table 2 ), a certain difference in correlation equations were found. Also in this case, correlation degrees for samples stored for 30 and 90 days are Bland-Altman analysis showed a good agreement between everolimus concentrations measured immediately after collection (LT0) and after storage periods (LT3O' LT 60and LT 90 ) , confirmed by the small number of values (3, 2 and 1 samples, respectively) exceeding the fixed range of mean±2SD ( Fig. 4,  panels d-f ).
DISCUSSION
The present study investigated the stability of Siro and Rad whole blood concentrations, in order to supply data on the appropriate handling of samples, in therapeutic drug monitoring.
In the case of Siro, the data obtained suggest the possibility of storing samples at 30°C in light for up to a week, with a decrement in drug concentration of 5.2%, a decrease that could be considered clinically not significant. Such data are in accordance with those reported by Salm and Yatscoff after a storage period of 8 or 30 days, respectively, at 30°C in light and dark (9-10). Therefore, our results confirm that the storage of samples in the dark is not a crucial point for assuring Siro stability for up to one week. Regarding long term stability, the present study highlights the possibility of storing samples up to 90 days at -20°C without significant variations, since an increment in drug concentrations <7% was found. In previous studies, Salm reported a substantial constancy of Siro concentrations in samples stored at -80°C for 6 weeks after one, two or three freezethaw cycles (9) , while Streit reported a significant decrease after storing samples at -40°C for 6 months and after two freeze-thaw cycles (11) . It is worth of note that in both previous trials the Authors used storage temperatures much lower than those presently worked.
The comparisons between sirolimus concentrations measured immediately after collection and those obtained after the storage periods presented excellent relationships, as confirmed by the significant high correlation degree (Fig. 1, panel  a and Fig. 3 , panels a-c, for short and long term stability, respectively). The Bland-Altman statistical analysis strengthened the agreement between data from fresh and stored samples; in fact for both short and long term stabilities almost all values fell within the statistically established limits of mean±2SD (Fig. 2 , panels a and b and Fig. 4 , panels a-c).
In the case of Rad a higher decrement in blood concentrations after three days of storage at 30°C in light was obtained with respect to Siro (-6.1% compared to -2.0%). However, the storing of samples for seven days resulted in no further Rad degradation. However, since such a decrement can be considered clinically not significant, it can be concluded that Rad blood samples can be stored at 30°C in light up to a week. Our data enlarge the stability range already reported in literature: stability at room temperature and exposure to light for 6 hours (12), and storage at room temperature for 15 hours (13) . With regard to long term stability, the data obtained highlight the possibility of storing samples for up to 90 days at -20°C without significant variations, since an increment in drug concentrations <6% was found. Also for everolimus the variations between stored and freshly analysed samples differ from literature data, since a decrement of -2.5% was found after 30 days of storage at -20°C, and variations of 5.9% and 2.1% were obtained after storage for 60 and 90 days. Salm reported a stability of 8 months when blood samples were stored at -80°C (12); Baldelli reported no significant loss in Rad blood concentrations after three freeze-thaw cycles and storage for 31 days below -20°C (13) .
The comparisons between everolimus concentrations measured immediately after collection and those obtained after the storage periods presented high correlations degrees ( Fig. 1,  panel b and Fig. 3 , panels d-f, for short and long term stability, respectively). Also in this case, the Bland-Altman test confirmed the agreement between data from fresh and stored samples, since for both short and long term stabilities almost all values felt within the statistically established limits ofmean±2SD (Fig.  2, panels c and d and Fig. 4, panels d-f ).
Data obtained by using LC/ESI-MSMS technique did not substantially differ from those found by using MEIA and FPIA, excluding the possibility of immunoassays cross-reactivity towards drug metabolites and confirming the validity and accuracy of the latter methods.
Findings on long term stability for both Siro and Rad highlight the possibility of storing samples at -20°C up to 90 days, without the need of using lower storage temperatures.
The possibility of storing Siro and Rad blood samples for up to three months at -20°C or at 30°C in light up to a week without any significant variations in drug concentrations has important implications for patients living far from labs where drug concentration is measured or when the storing of blood samples is needed for pharmacokinetic studies.
Moreover, present data extend to Rad the conclusion of Salm concerning external quality control programs for Siro, i.e., "samples could be stored in the reference laboratory and then transported frozen to each site" (12) .
In conclusion, frequent measurements of trough blood levels of both drugs are required. This condition could improve the cost-benefit ratio and help physicians take appropriate and fast decisions on the correct management of immunosuppressive dosages. In this setting, the correct storage of blood samples is of paramount clinical importance.
